Longitudinal analysis shows GAA1 length and baseline clinical status as robust predictors of progression in Friedreich ataxia


Por: Manrique, L, Martínez-Dubarbie, F, Pelayo-Negro, AL, Benitez-Calle, N, Sanchez-Pelaez, MV, Cota-Gonzalez, D, Loza, R, Martinez-Díaz, R, Irure-Ventura, J, Sanchez-Quintana, C, Sanchez, I, Matilla-Dueñas, A and Infante, J

Publicada: 9 abr 2026 Ahead of Print: 1 abr 2026
Resumen:
Friedreich's ataxia (FRDA) is the most common early onset hereditary ataxia, caused by GAA repeat expansions in the FXN gene. The length of the shorter allele (GAA1) and age at onset are established determinants of disease severity, though additional biomarkers such as frataxin expression and neurofilament light chain (NfL) have been proposed. We conducted a 30-month prospective longitudinal study, including 25 FRDA patients and 16 heterozygous carriers, assessing clinical progression through SARA, FARS-ADL, INAS, EQ-5D, SCAFI, and CCFS scales. Baseline measures included GAA repeats, frataxin expression in fibroblasts, CSF NfL, and disease burden. Frataxin levels were significantly reduced in patients and correlated with GAA1 length and baseline severity. SARA, FARS-ADL, and INAS worsened significantly over time, while SCAFI and CCFS remained stable. GAA1 length and baseline SARA score emerged as the strongest predictors of progression. CSF NfL was elevated in younger patients and declined with age but did not correlate with severity or progression. These results support GAA1 length and baseline clinical status as robust predictors of progression and suggest limited utility of CSF NfL as a longitudinal biomarker particularly in later disease stages.

Filiaciones:
Manrique, L:
 Hosp Univ Navarra, Neurol Dept, Pamplona, Spain

Martínez-Dubarbie, F:
 Hosp Univ Marques Valdecilla IDIVAL, Neurol Dept, Santander 39008, Spain

 Ctr Invest Biomed Red Enfermedades Neurodegenerat CIBERNED, Madrid, Spain

Pelayo-Negro, AL:
 Hosp Univ Marques Valdecilla IDIVAL, Neurol Dept, Santander 39008, Spain

 Ctr Invest Biomed Red Enfermedades Neurodegenerat CIBERNED, Madrid, Spain

Benitez-Calle, N:
 Univ Autonoma Barcelona, Res Inst Germans Trias & Pujol IGTP, Dept Neurosci, Neurogenet Unit, Campus Can Ruti, Badalona, Barcelona, Spain

 Biointaxis SL Badalona, Barcelona, Spain

Sanchez-Pelaez, MV:
 Hosp Univ Marques Valdecilla IDIVAL, Neurol Dept, Santander 39008, Spain

Cota-Gonzalez, D:
 Biointaxis SL Badalona, Barcelona, Spain

Loza, R:
 Hosp Univ Marques Valdecilla IDIVAL, Neurol Dept, Santander 39008, Spain

Martinez-Díaz, R:
 Hosp Univ Marques Valdecilla IDIVAL, Neurol Dept, Santander 39008, Spain

Irure-Ventura, J:
 Hosp Univ Marques Valdecilla IDIVAL, Dept Immunol, Santander, Spain

Sanchez-Quintana, C:
 Ctr Invest Biomed Red Enfermedades Neurodegenerat CIBERNED, Madrid, Spain

:
 Univ Autonoma Barcelona, Res Inst Germans Trias & Pujol IGTP, Dept Neurosci, Neurogenet Unit, Campus Can Ruti, Badalona, Barcelona, Spain

 Biointaxis SL Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona, Res Inst Germans Trias & Pujol IGTP, Dept Neurosci, Neurogenet Unit, Campus Can Ruti, Badalona, Barcelona, Spain

 Biointaxis SL Badalona, Barcelona, Spain

Infante, J:
 Hosp Univ Marques Valdecilla IDIVAL, Neurol Dept, Santander 39008, Spain

 Ctr Invest Biomed Red Enfermedades Neurodegenerat CIBERNED, Madrid, Spain

 Univ Cantabria UC, Santander, Spain
ISSN: 03405354





Journal of Neurology
Editorial
Dr. Dietrich Steinkopff Verlag, TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY, Alemania
Tipo de documento: Article
Volumen: 273 Número: 5
Páginas:
WOS Id: 001736568500003
ID de PubMed: 41954755
imagen Green Submitted, hybrid

MÉTRICAS